Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Licenses Caliper's In Vivo Imaging IP Suite

NEW YORK (GenomeWeb News) — Novartis has licensed Caliper Life Sciences’ intellectual property covering non-invasive optical imaging methods, Caliper said today.
Under the multi-year agreement, the drug maker will use Caliper’s Optical Imaging patent suite, which includes imaging systems, reagents, related applications, and methods and services, Caliper said.
According to Caliper, non-invasive optical imaging enables scientists to visualize, track, and quantify biological processes at the molecular level in vivo with high throughput and “relatively low cost.”
Caliper acquired its in vivo imaging technology through last year’s $80 million acquisition of Xenogen, at which point the company changed its name to Caliper Life Sciences.
Financial terms of the license were not released.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.